
北美干细胞治疗市场预测至 2028 年 - COVID-19 影响和区域分析(按类型(成人干细胞治疗、胚胎干细胞治疗、诱导多能干细胞治疗和其他干细胞治疗)、治疗(同种异体和自体)、应用(肌肉骨骼、皮肤科、心脏病学、药物发现和开发以及其他应用)和最终用户(医院和专科诊所以及学术和研究机构)
No. of Pages: 133 | Report Code: BMIRE00028486 | Category: Life Sciences
No. of Pages: 133 | Report Code: BMIRE00028486 | Category: Life Sciences
干细胞治疗已在世界各地得到广泛研究。干细胞主要用于替代垂死细胞和重建受损组织。根据迄今为止进行的广泛干细胞研究的结果,许多科学家声称这些细胞可能可用于治疗癌症和心血管疾病等疾病。新开发的干细胞疗法涉及用干细胞替代致病细胞。许多涉及干细胞的潜在治疗方法正处于临床试验的不同阶段。 FDA 还批准了一些涉及治疗干细胞移植相关并发症的干细胞疗法。 2021年9月,美国食品药品监督管理局(FDA)宣布批准“鲁索替尼”用于治疗12岁及以上患者的“移植物抗宿主病”(GVHD)。 Ruxolitinib 为患有干细胞移植相关致命并发症的患者带来了新的希望。
研究人员正在进一步研究干细胞疗法在治疗自身免疫性疾病中的应用。例如,干细胞可以转化为受损器官的细胞,并用于治疗自身免疫性疾病。使用间充质干细胞或胎儿干细胞进行治疗。造血干细胞目前用于治疗80多种疾病,包括免疫系统疾病、血液疾病、神经系统疾病、代谢性疾病、遗传性疾病以及白血病和淋巴瘤等癌症类型。
北美干细胞治疗市场概述
北美干细胞治疗市场已细分为美国、加拿大、和墨西哥。 2021年,美国在北美干细胞治疗市场中占据最大份额。人们对利用干细胞治疗疾病的认识不断增强,干细胞治疗研究和治疗的优惠报销政策也越来越广泛。开发活动、对干细胞库的日益重视以及该市场主要参与者的主要存在预计将加速干细胞治疗市场的增长。
在加拿大,由于医疗保健系统的发展和对干细胞治疗技术的投资迅速增加,预计市场将会增长。另一方面,在墨西哥,由于人们对干细胞治疗益处的认识不断提高,预计墨西哥的干细胞治疗市场可能会经历增长机会。
北美干细胞治疗市场分为类型、治疗、应用、最终用户和国家。
北美干细胞治疗细胞治疗市场按类型分为成体干细胞治疗、诱导多能干细胞治疗、胚胎干细胞治疗和其他干细胞治疗。成体干细胞治疗领域在 2022 年占据最大的市场份额。
根据治疗,北美干细胞治疗市场分为同种异体和自体干细胞治疗。到2022年,同种异体干细胞治疗市场占据最大份额。
根据应用,北美干细胞治疗市场分为肌肉骨骼、皮肤病学、心脏病学、药物发现和开发、其他应用。到 2022 年,肌肉骨骼领域将占据最大的市场份额。
北美干细胞治疗市场按最终用户划分,分为学术和干细胞治疗。研究机构和医院诊所。学术与研究机构细分市场在 2022 年占据最大市场份额。
按国家/地区划分,北美干细胞治疗市场分为美国、加拿大和墨西哥。美国在 2022 年占据市场主导地位。
MEDIPOST;富源; BioTime公司;中胚层有限公司;美国干细胞公司; TiGenix NV; Allo源;和 NuVasive Inc 是北美干细胞治疗市场的领先公司。
Strategic insights for North America Stem Cell Therapy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 1,299.39 Million |
Market Size by 2028 | US$ 3,582.26 Million |
Global CAGR (2022 - 2028) | 18.4% |
Historical Data | 2020-2021 |
Forecast period | 2023-2028 |
Segments Covered |
By 类型
|
Regions and Countries Covered | 北美
|
Market leaders and key company profiles |
The regional scope of North America Stem Cell Therapy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The North America Stem Cell Therapy Market is valued at US$ 1,299.39 Million in 2022, it is projected to reach US$ 3,582.26 Million by 2028.
As per our report North America Stem Cell Therapy Market, the market size is valued at US$ 1,299.39 Million in 2022, projecting it to reach US$ 3,582.26 Million by 2028. This translates to a CAGR of approximately 18.4% during the forecast period.
The North America Stem Cell Therapy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Stem Cell Therapy Market report:
The North America Stem Cell Therapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Stem Cell Therapy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Stem Cell Therapy Market value chain can benefit from the information contained in a comprehensive market report.